Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562809 | 0.87 | TAAR1 (0.75) | TAAR1SHBGESR1ESR2NPC1 | |
| Hydrochloric Acid SCHEMBL6563360 | 0.85 | TAAR1 (0.71) | TAAR1HTR2CSHBGESR1ESR2 | |
| SCHEMBL5877849 | 0.80 | TAAR1 (0.65) | TAAR1CA1CA2CA9ALDH1A1 | |
| SCHEMBL10961852 | 0.80 | TAAR1 (0.65) | TAAR1SHBGESR1ESR2NPC1 | |
| SCHEMBL12171 | 0.78 | TAAR1 (0.62) | TAAR1SHBGESR1ESR2NPC1 | |
| SCHEMBL10574062 | 0.78 | TAAR1 (0.62) | TAAR1ALDH1A1MAPK1SHBGESR1 | |
| SCHEMBL3239365 | 0.78 | NPC1 (0.48) | CYP2A6ALDH1A1MAPK1SHBGNPC1 | |
| SCHEMBL8350486 | 0.78 | TAAR1 (0.62) | TAAR1HTR2ACYP2A6CA1CA2 | |
| SCHEMBL7839746 | 0.77 | HTR2C (0.38) | TAAR1HTR2ACYP2A6CA1CA2 | |
| SCHEMBL3045994 | 0.76 | CNR1 (0.42) | TAAR1CYP2A6CA1CA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970176-B1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3761978-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2020-12-24 | — | — | US | disclosed |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2020-12-24 | — | — | US | disclosed |
| CN-107573295-B | Molecules and intermediates having pesticidal utility, compositions and methods relating thereto | 美国陶氏益农公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-111825656-A | Inhibitors of protein arginine methyltransferase 5(PRMT5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2019173804-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2019-09-12 | — | — | WO | disclosed |
| CN-103987697-A | Substituted tetrahydroisoquinoline compounds as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2014-08-13 | — | — | CN | disclosed |
| CN-102834394-A | Bicyclic quinolone compounds, preparation and application thereof | KBP BIOSCIENCES CO LTD | 2012-12-19 | — | — | CN | disclosed |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012028676-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011124093-A1 | BICYCLIC QUINOLONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-10-13 | — | — | WO | disclosed |
| CN-102212056-A | Novel bicyclo-carbostyril compounds | KBP BIOSCIENCES CO LTD | 2011-10-12 | — | — | CN | disclosed |
| US-6358974-B1 | USED AS AS MODULATORS OF DOPAMINE D.SUB.3 RECEPTORS, IN THERAPY AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-19 | — | — | US | disclosed |
| EP-1137638-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000024717-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | TFPI, F12, F11 | TAAR1 4230/4885HTR2A 1194/4885CYP2A6 880/4885 |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PRMT5, PRMT1, PRMT3 | TAAR1 2651/4885HTR2A 4840/4885CYP2A6 4281/4885 |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | TAAR1 4681/4885HTR2A 3423/4885CYP2A6 233/4885 |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PRMT5, PRMT1, PRMT3 | TAAR1 2651/4885HTR2A 4840/4885CYP2A6 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.